116435-82-6

Basic information

• Product Name: BENZENEACETIC ACID, 4-AMINO-3-NITRO-
• Synonyms: BENZENEACETIC ACID, 4-AMINO-3-NITRO-;4-amino-3-nitroBenzeneacetic acid
• CAS NO: 116435-82-6
• Molecular Formula: C₈H₈N₂O₄
• Molecular Weight: 196.16
• Mol File: 116435-82-6.mol
• Article Data: 2

Chemical Properties

• Melting Point: 144-145 °C
• Boiling Point: 449.3±30.0 °C(Predicted)
• Appearance: /
• Density: 1.497±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 4.41±0.10(Predicted)
• CAS DataBase Reference: BENZENEACETIC ACID, 4-AMINO-3-NITRO-(CAS DataBase Reference)
• NIST Chemistry Reference: BENZENEACETIC ACID, 4-AMINO-3-NITRO-(116435-82-6)
• EPA Substance Registry System: BENZENEACETIC ACID, 4-AMINO-3-NITRO-(116435-82-6)

Safety Data

• Hazardous Substances Data: 116435-82-6(Hazardous Substances Data)

Upstream product

• 1197-55-3 4-aminophenylacetic acid 
• 25025-06-3 N-(4-cyanomethyl-phenyl)-acetamide 
• 3544-25-0 p-aminophenylacetonitrile 
• 118380-03-3 methyl 3-(4-acetamidophenyl)propanoate 
• 39552-81-3 methyl p-aminophenylacetate 
• 303050-39-7 methyl 2-(4-acetamido-3-nitrophenyl)acetate 
• 123270-23-5 acetic acid-(4-cyanomethyl-2-nitro-anilide) 

Downstream Products

• 1026426-43-6 4-{2-[((R)-5-Methoxy-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl)-methyl-amino]-ethyl}-benzene-1,2-diamine 
• 473895-87-3 ethyl ester of quinoxalin-6-ylacetic acid 
• 85907-78-4 ethyl 2-(3,4-diaminophenyl)acetate 
• 1026940-70-4 2-(4-Amino-3-nitro-phenyl)-N-((R)-5-methoxy-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl)-N-methyl-acetamide 
• 621-43-2 (3,4-diamino-phenyl)-acetic acid 
• 104126-70-7 2-(4-amino-3-nitrophenyl)acetic acid ethyl ester 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR

Disclosed are heterocyclic compounds as inhibitors of FGFR-4 represented by formula (I). Also disclosed is a pharmaceutical composition that includes an inhibitor of FGFR-4. The compounds maybe used to treat diseases mediated with abnormality of FGFR-4 and /or FGF19, such as hepatocellular carcinoma and other forms of cancer.